PMID- 38364746
OWN - NLM
STAT- MEDLINE
DCOM- 20240226
LR  - 20240226
IS  - 1878-1705 (Electronic)
IS  - 1567-5769 (Linking)
VI  - 129
DP  - 2024 Mar 10
TI  - Oroxylin A suppress LL-37 generated rosacea-like skin inflammation through the 
      modulation of SIRT3-SOD2-NF-kappaB signaling pathway.
PG  - 111636
LID - S1567-5769(24)00154-1 [pii]
LID - 10.1016/j.intimp.2024.111636 [doi]
AB  - Rosacea is a long-term inflammatory skin disease associated with the dysfunction 
      of vascular and immunological systems. Treatment options for rosacea are 
      difficult to implement. Oroxylin A(OA), a traditional Chinese medicine, has 
      anti-inflammation effects in a variety of inflammatory diseases. However, it is 
      not known that whether OA exerts protective effects against LL-37-induced 
      rosacea. In this study, bioinformatics analyses showed that the mechanisms of 
      rosacea and the pharmacological targets of OA were highly overlapped. 
      Subsequently, it was shown that the administration of OA resulted in a notable 
      amelioration of rosacea-like skin lesions, as evidenced by a reduction in immune 
      cell infiltration, modulation of cytokine production, and inhibition of 
      angiogenesis. Plus, it was shown that OA effectively suppressed the generation of 
      ROS generated by LL-37, as well as the subsequent activation of NF-kappaB signaling 
      pathway. To explore further, we found that OA inhibited LL-37-induced ROS 
      production via SIRT3-SOD2 signaling pathway in keratinocytes. Based on the 
      aforementioned evidence, it can be inferred that OA exhibits a mitigating effect 
      on the inflammatory response in rosacea by modulating the SIRT3-SOD2-NF-kappaB 
      signaling pathway.
CI  - Copyright (c) 2024 Elsevier B.V. All rights reserved.
FAU - Feng, Chunmei
AU  - Feng C
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China.
FAU - Zhang, Haiyan
AU  - Zhang H
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China.
FAU - Wang, Peiru
AU  - Wang P
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China.
FAU - Zhang, Linglin
AU  - Zhang L
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China.
FAU - Liu, Xiaojing
AU  - Liu X
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China.
FAU - Yan, Guorong
AU  - Yan G
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China.
FAU - Yan, Yu
AU  - Yan Y
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China.
FAU - Yang, Jin
AU  - Yang J
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China.
FAU - Liu, Jia
AU  - Liu J
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China.
FAU - Tan, Fei
AU  - Tan F
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China. Electronic address: 
      tanfeitrue@126.com.
FAU - Wang, Xiuli
AU  - Wang X
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China. Electronic address: 
      wangxiuli_1400023@tongji.edu.cn.
FAU - Zeng, Qingyu
AU  - Zeng Q
AD  - Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui 
      Medical University, Shanghai Skin Disease Hospital, Shanghai 200443, China; 
      Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, 
      Tongji University, Shanghai 200443, China. Electronic address: 
      zengqingyu2011@tongji.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20240215
PL  - Netherlands
TA  - Int Immunopharmacol
JT  - International immunopharmacology
JID - 100965259
RN  - 0 (NF-kappa B)
RN  - 53K24Z586G (5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one)
RN  - EC 3.5.1.- (Sirtuin 3)
RN  - 0 (Reactive Oxygen Species)
RN  - EC 3.5.1.- (SIRT3 protein, human)
RN  - 0 (Flavonoids)
SB  - IM
MH  - Humans
MH  - NF-kappa B/metabolism
MH  - *Sirtuin 3/metabolism
MH  - Reactive Oxygen Species/metabolism
MH  - *Rosacea/drug therapy
MH  - *Dermatitis
MH  - Signal Transduction
MH  - Inflammation/drug therapy
MH  - *Flavonoids
OTO - NOTNLM
OT  - NF-kappaB
OT  - Oroxylin A
OT  - ROS
OT  - Rosacea
OT  - SIRT3
OT  - SOD2
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/02/17 10:42
MHDA- 2024/02/26 06:43
CRDT- 2024/02/16 18:16
PHST- 2023/12/16 00:00 [received]
PHST- 2024/01/28 00:00 [revised]
PHST- 2024/01/30 00:00 [accepted]
PHST- 2024/02/26 06:43 [medline]
PHST- 2024/02/17 10:42 [pubmed]
PHST- 2024/02/16 18:16 [entrez]
AID - S1567-5769(24)00154-1 [pii]
AID - 10.1016/j.intimp.2024.111636 [doi]
PST - ppublish
SO  - Int Immunopharmacol. 2024 Mar 10;129:111636. doi: 10.1016/j.intimp.2024.111636. 
      Epub 2024 Feb 15.